Navigation Links
KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10-K
Date:6/22/2009

ST. LOUIS, June 22 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) (the "Company") today announced that it received a letter from NYSE Regulation, Inc. (the "NYSE") on June 16, 2009 informing the Company that it is subject to certain procedures as specified in Section 802.01E of the NYSE's Listed Company Manual ("Section 802.01E") as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended March 31, 2009 (the "2009 Annual Report") with the Securities and Exchange Commission (the "SEC").

Section 802.01E provides that the NYSE will monitor the Company and the status of the Company's filing of the 2009 Annual Report for a six-month period from the filing due date for the 2009 Annual Report. If the 2009 Annual Report is not filed with the SEC upon expiration of such six-month period, the NYSE will, in its sole discretion, determine whether to provide the Company with an additional six-month period in which to file the 2009 Annual Report. The letter also states that, regardless of the procedures specified in Section 802.01E and if circumstances warrant, the NYSE could commence delisting procedures at any time during any period that is available to complete the filing of the 2009 Annual Report.

As previously disclosed in its Notification of Late Filing on Form 12b-25 filed with the SEC on June 2, 2009, the Company has been unable to timely file the 2009 Annual Report due to an ongoing internal investigation being conducted by the Audit Committee (the "Audit Committee") of the Board of Directors of the Company. While the Audit Committee's investigation has been substantially completed, the Audit Committee has referred certain matters with a potential financial reporting impact resulting from its investigation to management for resolution. Until these matters can be resolved, the Company will not be in a position to file the 2009 Annual Report with the SEC. The
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
(Date:4/23/2014)... O,Shea, M.D., scientific director at the National Institute of ... named the 2014 recipient of the Ross Prize in ... journal Molecular Medicine . The award will be ... of Sciences in Manhattan, followed by scientific presentations by ... of the National Institutes of Health. , The award, ...
(Date:4/23/2014)... Society for Radiation Oncology (ASTRO) has issued a ... for Endometrial Cancer: An ASTRO Evidence-Based Guideline," that ... the treatment of endometrial cancer. The guideline,s executive ... of Practical Radiation Oncology (PRO), the ... guideline is available as an open-access article online ...
(Date:4/23/2014)... - Purdue University researchers have developed a way to ... by using tiny gold particles with tails of synthetic ... agricultural and biological engineering, used gold nanoparticles to target ... BRCA1 messenger RNA splice variants, which can indicate the ... these mRNA splice variants in a cell can be ...
(Date:4/23/2014)... targets an important brain receptor has a dramatic effect ... behavior, a University at Buffalo animal study has found. ... be a novel lead compound for treating cocaine addiction, ... was published as an online preview article in ... compound, RO5263397, severely blunted a broad range of cocaine ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... ... Flying Marijuana Bud Banner On Labor Day Weekend , ... Seattle, WA (PRWEB) September 4, 2009 -- When Labor Day crowds ... a flying marijuana bud on a massive banner along with the words "Want Big, Sugary ...
... ... Channel on the Fast Growth 100 list. The Fast Growth 100 recognizes the fastest growing ... , ... 4, 2009 -- Netelligent today announced that it has been recognized by Everything Channel on ...
... ... its short term medical insurance product to HCC Life Short Term Medical (STM). , ... Indianapolis, IN (PRWEB) September 3, 2009 ... term medical insurance product to HCC Life Short Term Medical (STM). Formerly known ...
... , , PALO ALTO, Calif., ... announced today that company management will present a corporate overview at ... Myers, President of Jazz Pharmaceuticals, will speak at the Rodman & ... 3:15 p.m. EDT at the Palace Hotel in New York City. ...
... say more research is needed , THURSDAY, Sept. 3 (HealthDay ... a new Danish study indicates they might also raise the ... and women. , That,s not to say fat thighs confer ... nearly 3,000 men and women who were followed for more ...
... , , , SAN FRANCISCO, ... will be ensuring expedited access to needed prescriptions and mental health ... California. , , "During this taxing and difficult ... people impacted by the wildfires to continue to have uninterrupted access ...
Cached Medicine News:Health News:Labor Day Beach Visitors Will See Giant Hydroponics Marijuana Bud Banner Flying Over Los Angeles & San Diego 2Health News:Labor Day Beach Visitors Will See Giant Hydroponics Marijuana Bud Banner Flying Over Los Angeles & San Diego 3Health News:Netelligent Recognized on the Everything Channel Fast Growth 100 List at #13 2Health News:Netelligent Recognized on the Everything Channel Fast Growth 100 List at #13 3Health News:HCC Life Insurance Company Renames Short Term Medical Insurance 2Health News:Thin Thighs Might Be Harbinger of Heart Disease 2Health News:Blue Shield of California Streamlines Access to Benefits and Prescriptions for Wildfire Victims 2
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , June 2 Today, the U.S. Food and Drug ... active ingredient known as a long-acting beta-agonist (LABA).  This follows the FDA ... medications to undertake class-labeling changes. , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) , ...
... , June 2 GlaxoSmithKline (NYSE: ... a letter from the U.S. Food and Drug Administration ... Serevent® and Advair®.  The letter concludes discussions between GSK ... the safety profile of long-acting beta2-agonists in the treatment ...
Cached Medicine Technology:FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 2FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 3FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 4FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 5FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 6GSK Announces Revised Product Labels for Serevent® and Advair® 2
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Model C-18 is made of ... padding. Front and back sections ... larger openings to facilitate air ... is lightweight and washable. Model ...
Ezy Wrap® Economy Contour Cervical Collar Medium-density urethane foam. Synthetic white stockinette cover. Reverses for flexion or extension. (Contact closure. Hand wash. Air dry. 10/pack.)...
... improves patient compliance, prevent skin breakdown ... user's anatomy, wicks moisture, and evenly ... shoulders and upper throacic. Fits upright ... airflow openings. Adjustable Occipital Support Strap™ ...
Medicine Products: